# US 2001/0044471 A1 · Novel process to prepare 2-aminoindan derivatives

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2001/0044471 A1
- Document ID: US20010044471A1
- Status: Published application
- Kind: A1
- Application number: 09/783,649
- Filed: 2001-02-14
- Published: 2001-11-22
- Earliest claimed: 2000-02-22
- Assignees: Pharmacia & Upjohn Company
- Inventors: Arthur Glenn Romero; Thomas Andrew Runge; Bradley D. Hewitt; Kjell Anders Ivan Svensson; Chiu-Hong Lin; Kerry Anne Cleek; Susanne R. Haadsma-Svensson
- Web page: https://patentgrep.com/patent/US20010044471A1

## CPC

- C07C 217/74: with rings other than six-membered aromatic rings being part of the carbon skeleton
- A61P 1/00: Drugs for disorders of the alimentary tract or the digestive system
- A61P 3/04: Anorexiants; Antiobesity agents
- A61P 9/00: Drugs for disorders of the cardiovascular system
- A61P 25/00: Drugs for disorders of the nervous system
- A61P 25/06: Antimigraine agents
- A61P 25/14: for treating abnormal movements, e.g. chorea, dyskinesia
- A61P 25/16: Anti-Parkinson drugs
- A61P 25/18: Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
- A61P 25/20: Hypnotics; Sedatives
- A61P 25/22: Anxiolytics
- A61P 25/24: Antidepressants
- A61P 25/28: for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A61P 37/04: Immunostimulants
- C07C 237/48: having the carbon atom of at least one of the carboxamide groups bound to a carbon atom of a six-membered aromatic ring being part of a condensed ring system of the same carbon skeleton
- C07B 2200/07: Optical isomers
- C07C 2602/08: the other ring being five-membered, e.g. indane
- C07C: ACYCLIC OR CARBOCYCLIC COMPOUNDS
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07B: GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR (preparation of carboxylic acid esters by telomerisation C07C67/47; telomerisation C08F)

## Abstract

The present invention relates to (2S)-enantiomers of 2-aminoindan derivatives of formula I: 1 and a novel process for the preparation of them.

## Claims

### Claim 1

A compound of formula I
16
or a pharmaceutically acceptable salt thereof wherein each R is independently C1-8 alkyl.

### Claim 2

A compound of formula 1 as shown in claim I which is (2S)-(+)-2-(dipropylamino)-6-ethoxy-2,3-dihydro-1H-indene-5-carboxamide or a pharmaceutically acceptable salt thereof.

### Claim 3

A process for preparing a compound of formula I
17
wherein each R is independently C1-8 alkyl which comprises steps of
a) hydrogenation of compound of I-1 to compound I-2 as a racemic mixture
18
in the presence of an appropriate catalyst and an appropriate solvent;
b) resolution of compound I-2 to compound I-2b
19
chiral acid
by treating compound I-2 with a chiral acid in an appropriate solvent;
c) alkylation of I-2b in the presence of a base and an appropriate solvent system to provide compound I-3;
20
d) converting compound I-3 to compound I-4;
21
e) bromination of compound I-4 to compound I-5;
22
with a brominating reagent in the presence of an acid and an appropriate solvent system; and
f) carboxamidation I-5 in the presence of transition metal and an associated ligand in an appropriate solvent with an appropriate base, or alternatively treating 1-5 with an alkyllithium followed by trimethylsilylisocyanate, to provide a compound of formula I.

### Claim 4 (depends on 3)

A process of claim 3 wherein said chiral acid is tartaric acid, di-benzoyltartaric acid, di-para-toluoyltartaric acid, camphorsulfonic acid, or mandelic acid.

### Claim 5 (depends on 3)

A process of claim 3 wherein the chiral acid is (1R)-(−)-I0-camphorsulfonic acid, or (R)-(−)-mandelic acid.

### Claim 6 (depends on 3)

A process of claim 3 wherein said appropriate solvent system in step b) is a mixture of methanol and tetrahydrofuran.

### Claim 7 (depends on 3)

A process of claim 3 wherein said brominating reagent in step d) is pyridinium tribromide.

### Claim 8 (depends on 3)

A process of claim 3 wherein said transition metal in step e) is palladium, palladium on carbon or palladium acetate and said associated ligand is triphenylphosphine, tri-orthotolulyphosphine, or 1,3-bis(diphenylphosphino)propane.

### Claim 9 (depends on 1)

An intermediate of I-2b or its chiral salt for the preparation of a compound of formula I as shown in claim 1
23
chiral acid
wherein R is C1-8 alkyl.

### Claim 10 (depends on 9)

An intermediate of claim 9 which is (1S, 2S)-trans-(−)-2-amino-6-ethoxy-2,3-dihydro-1H-inden-1-o or its chiral salt.

### Claim 11 (depends on 9)

An intermediate of claim 9 which is (1S, 2S)-trans-(−)-2-amino-6-ethoxy-2,3-dihydro-1H-inden-1-ol (R)-(−)-mandelate.

### Claim 12 (depends on 1)

An intermediate selected from a group consisting of I-3, I-4, or I-5 for the preparation of a compound of formula I as shown in claim 1
24
wherein each R is independently C1-8 alkyl.

### Claim 13 (depends on 12)

An intermediate of claim 12 which is (1S, 2S)-trans-2-(dipropylamino)-6-ethoxy-2,3-dihydro-1H-inden-1-ol or a pharmaceutically acceptable salt thereof.

### Claim 14 (depends on 12)

An intermediate of claim 12 which is (2S)-5-ethoxy-2,3-dihydro-N,N-dipropyl-1H-inden-2-amine or a pharmaceutically acceptable salt thereof.

### Claim 15 (depends on 12)

An intermediate of claim 12 which is (R)-5-bromo-6-ethoxy-2,3,-dihydro-N,N,-dipropyl -1H-inden-2-amine or a pharmaceutically acceptable salt thereof.

### Claim 16 (depends on 1)

A method for treating or preventing a central nervous system disorder associated with dopamine D3 receptor activity comprising administering to a mammal in need thereof an effective amount of formula I as shown in claim 1.

### Claim 17 (depends on 16)

The method of claim 16 wherein said disorder is anxiety, obesity, depression, schizophrenia, a stress related disease, panic disorder, sleep disorders, a phobia, mania, obsessive compulsive disorder, post-traumatic-stress syndrome, immune system depression, a stress induced problem with the gastrointestinal or cardiovascular system, or sexual dysfunction.

### Claim 18 (depends on 16)

The method of claim 16 wherein said disorder is attention deficit hyperactivity disorder, migraine, substance abuse, cognitive deficits, memory impairment, alzheimer's disease, movement disorders, disease, motor complications, extrapyramidal side effects related to the use of neuroleptics, or “Tics” including Tourette's syndrome.

### Claim 19 (depends on 18)

The method of claim 18 wherein said substance abuse is drug abuse or smoking abuse; wherein movement disorder is choreatic movements in huntington's; wherein motor complications are dystonias and dyskinesias in Parkinson's disease.
